Atomoxetine is a non‐stimulant drug licensed for use in the treatment of attention deficit‐hyperactivity disorder (ADHD).Dr Banerjee describes a study that was carried out over a two‐year period in the three ADHD clinics in East Kent Hospitals NHS Trust to evaluate the current practice on the use of atomoxetine in ADHD in children and adolescents.
No takes yet. Share an insight, caveat, or question.
Somnath Banerjee (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: